Literature DB >> 17023533

Kisspeptins are novel potent vasoconstrictors in humans, with a discrete localization of their receptor, G protein-coupled receptor 54, to atherosclerosis-prone vessels.

Emma J Mead1, Janet J Maguire, Rhoda E Kuc, Anthony P Davenport.   

Abstract

The G protein-coupled receptor GPR54 (also designated KISS1) is activated by cleavage products of the KiSS1 protein, the kisspeptins (KP), to act as a molecular switch for puberty. Additionally, KP are potent inhibitors of tumor metastasis and play a role in placentation, both processes involving angiogenesis. Our aim was to investigate whether GPR54 and KP are expressed within normal and diseased human vasculature and what their functional role may be. RT-PCR screening of human blood vessels revealed a discrete localization of GPR54 mRNA in smooth muscle of vessels with the same developmental origins, aorta, coronary artery, and umbilical vein, a pattern confirmed by immunocytochemistry and radioligand binding. Novel ligand [(125)I]KP-13 exhibited saturable and high-affinity binding in aorta smooth muscle sections (dissociation constant K(D) = 0.2 +/- 0.03 nM), and using confocal microscopy, we found colocalization of receptor and peptide to vascular endothelial cells and to the atherosclerotic plaque of coronary artery. RIA detected 13.04 +/- 2.94 and 20.50 +/- 5.00 fmol/g KP in human coronary artery and aorta, respectively. KP-10, KP-13, and KP-54 acted as vasoconstrictors with comparable potency and efficacy in isolated rings of coronary artery (negative logarithm of the EC(50) and maximal response, respectively, as follows: KP-10, 7.89 +/- 0.24 and 33.7 +/- 17.0; KP-13, 8.66 +/- 0.88 and 35.1 +/- 7.9; KP-54, 8.86 +/- 1.11 and 25.7 +/- 5.5) and umbilical vein (negative logarithm of the EC(50) and maximal response, respectively, as follows: KP-10, 8.44 +/- 022 and 24.3 +/- 3.7; KP-13, 8.43 +/- 0.88 and 28.4 +/- 8.6; KP-54, 8.93 +/- 0.39 and 36.9 +/- 5.2). In conclusion, we have detected expression of both peptide and receptor in aorta, coronary artery, and umbilical vein and have shown for the first time that the KP are vasoconstrictors in humans, suggesting a previously undescribed role for GPR54 and KP in the cardiovascular system.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17023533     DOI: 10.1210/en.2006-0818

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  39 in total

Review 1.  International Union of Basic and Clinical Pharmacology. LXXVII. Kisspeptin receptor nomenclature, distribution, and function.

Authors:  Helen R Kirby; Janet J Maguire; William H Colledge; Anthony P Davenport
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 2.  Kisspeptin signalling in the physiology and pathophysiology of the urogenital system.

Authors:  Fazal Wahab; Bibi Atika; Muhammad Shahab; Rüdiger Behr
Journal:  Nat Rev Urol       Date:  2015-12-01       Impact factor: 14.432

3.  Dynamics of the transcriptome in the primate ovulatory follicle.

Authors:  Fuhua Xu; Richard L Stouffer; Jörg Müller; Jon D Hennebold; Jay W Wright; Alistair Bahar; Gabriele Leder; Michaele Peters; Melissa Thorne; Micaela Sims; Tim Wintermantel; Bernhard Lindenthal
Journal:  Mol Hum Reprod       Date:  2010-10-29       Impact factor: 4.025

4.  The effects of kisspeptin-54 on blood pressure in humans and plasma kisspeptin concentrations in hypertensive diseases of pregnancy.

Authors:  Gurjinder M K Nijher; Owais B Chaudhri; Radha Ramachandran; Kevin G Murphy; Sagen E K Zac-Varghese; Alexis Fowler; Krishna Chinthapalli; Michael Patterson; Emily L Thompson; Catherine Williamson; Sailesh Kumar; Mohammad A Ghatei; Stephen R Bloom; Waljit S Dhillo
Journal:  Br J Clin Pharmacol       Date:  2010-11       Impact factor: 4.335

5.  Kisspeptins: a multifunctional peptide system with a role in reproduction, cancer and the cardiovascular system.

Authors:  E Votsi; D Roussos; I Katsikis; A Karkanaki; M Kita; D Panidis
Journal:  Hippokratia       Date:  2008       Impact factor: 0.471

6.  Presence of kisspeptin-like immunoreactivity in human adrenal glands and adrenal tumors.

Authors:  Kazuhiro Takahashi; Itaru Shoji; Akiko Shibasaki; Ichiro Kato; Keisuke Hiraishi; Hajime Yamamoto; Kiriko Kaneko; Osamu Murakami; Ryo Morimoto; Fumitoshi Satoh; Sadayoshi Ito; Kazuhito Totsune
Journal:  J Mol Neurosci       Date:  2009-11-07       Impact factor: 3.444

7.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

8.  Maternal Engineered Nanomaterial Inhalation During Gestation Disrupts Vascular Kisspeptin Reactivity.

Authors:  Elizabeth C Bowdridge; Alaeddin B Abukabda; Kevin J Engles; Carroll R McBride; Thomas P Batchelor; William T Goldsmith; Krista L Garner; Sherri Friend; Timothy R Nurkiewicz
Journal:  Toxicol Sci       Date:  2019-06-01       Impact factor: 4.849

Review 9.  Kisspeptin signaling in the brain.

Authors:  Amy E Oakley; Donald K Clifton; Robert A Steiner
Journal:  Endocr Rev       Date:  2009-09-21       Impact factor: 19.871

10.  Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia.

Authors:  Anastasia Murat; Eugenia Migliavacca; S Farzana Hussain; Amy B Heimberger; Isabelle Desbaillets; Marie-France Hamou; Curzio Rüegg; Roger Stupp; Mauro Delorenzi; Monika E Hegi
Journal:  PLoS One       Date:  2009-06-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.